Heat Shock Protein 105 (HSP105) peptide-pulsed dendritic cell vaccination therapy for patients with advanced/ recurrent cancer.
Not Applicable
- Conditions
- Advanced/recurrent cancer (pancreatic cancer, colon cancer, biliary tract cancer, esophageal cancer, pharynx cancer, breast cancer etc.)
- Registration Number
- JPRN-UMIN000006730
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
Not provided
Exclusion Criteria
1) Pulmonary fibrosis or interstitial pneumonia, including their history or predisposition; 2) Serious drug allergy; 3) Difficult infections to control; 4) Serious cardiac disease; 5) Active autoimmune diseases; 6) Other cancers; 7) Continuous systemic administration of steroids and/or immunosuppressants within 4 weeks.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Immunological responses Antitumor effect Overall survival Progression-free survival